Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain μ locus and c-myc
- 1 June 2000
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 14 (6) , 1127-1135
- https://doi.org/10.1038/sj.leu.2401767
Abstract
Hyperplastic plasmacytotic lymph nodes and Peyer's patches of 12 of 25 (48%) BALB/c mice that carried a human IL-6 transgene under the transcriptional control of the histocompatibility H-2LD promoter (BALB/c.IL-6 mice) were found to harbor 15 cell clones that contained in their T(12;15) translocation breakpoint regions illegitimate genetic recombinations between the upstream flank of the immunoglobulin heavy-chain Cμ locus (5′-Cμ) and c-myc(5′-Cμ/c-myc+ clones). Similar 5′-Cμ/c-myc+ clones were also detected in pristane-induced peritoneal granulomata (a significant source of IL-6 in situ) of three of 13 (13%) conventional BALB/c mice, but not in lymphoid tissues of pristane-treated BALB/c mice, nor in any tissue of untreated BALB/c mice. These findings provided strong evidence that IL-6 may be able to promote the growth and/or survival of clones that contained rearrangements between 5′-Cμ and c-myc. Taken in conjunction with our previous observation that 5′-Cμ/c-myc+ clones are the precursors for pristane-induced BALB/c plasmacytomas, the findings further suggested that IL-6 may play a pivotal role in the early stage of plasmacytoma development, by promoting tumor precursor cells. The BALB/c.IL-6 model of plasmacytomagenesis may be superior to the conventional BALA/c model because the putative plasmacytoma precursors appear to be more prevalent and in their development independent of treating the mice with inflammation-inducing plasmacytomagenic agents, such as pristane or silicone polymers.Keywords
This publication has 29 references indexed in Scilit:
- Mechanisms of apoptosis by c-MycOncogene, 1999
- Deletional remodeling of c-myc-deregulating chromosomal translocationsOncogene, 1997
- Distinct Tumorigenic Potential of abl and raf in B Cell Neoplasia: abl Activates the IL-6 Signaling PathwayImmunity, 1996
- DNA sequence analysis of the genetIc recombination betweenIgh6 andMyc ln an uncommon BALB/c plasmacytoma, TEPC 1194Immunogenetics, 1996
- Interleukin 6 is essential for in vivo development of B lineage neoplasms.The Journal of Experimental Medicine, 1995
- Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.Genes & Development, 1994
- Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.The Journal of Experimental Medicine, 1990
- A Macrophage-Derived Factor Required by Plasmacytomas for Survival and Proliferation in VitroScience, 1986
- Control of Immunoglobulin Class Switch RecombinationImmunological Reviews, 1986
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985